Analysts See $0.71 EPS for Abbott Laboratories (ABT) as of July, 19

June 29, 2018 - By Robert Case

Abbott Laboratories (NYSE:ABT) Corporate Logo
During Q1 2018 the big money sentiment decreased to 0.83. That’s change of 0.08, from 2017Q4’s 0.91. 44 investors sold all, 606 reduced holdings as Abbott Laboratories ratio dropped. 411 grew holdings while 126 funds took holdings. Funds hold 1.22 billion shares thus 0.54% more from 2017Q4’s 1.22 billion shares.
Birch Hill Inv Advsrs Limited Liability Co invested in 0.15% or 30,449 shs. Bancshares Of Montreal Can stated it has 2.14 million shs or 0.11% of all its holdings. Tealwood Asset Mgmt Incorporated reported 35,435 shs. Cornerstone Advsr reported 446 shs or 0.02% of all its holdings. Baxter Bros Incorporated reported 0.08% stake. Washington Trust Company holds 116,776 shs. Td Asset Mngmt, a Ontario – Canada-based fund reported 1.51M shs. L S Advisors Inc invested in 0.24% or 21,348 shs. Boston Family Office Llc invested in 0.71% or 104,258 shs. Savings Bank Of Nova Scotia accumulated 452,875 shs. 289,299 were reported by Sawgrass Asset Ltd Liability Corp. Centurylink Mgmt Company reported 15,619 shs or 0.34% of all its holdings. Birmingham Management Communication Al reported 32,438 shs. Eagle Glob Advisors Lc reported 4,901 shs stake. Corbyn Invest Md has 0.24% invested in Abbott Laboratories (NYSE:ABT).

Abbott Laboratories had 20 selling transactions and 1 buy since January 30, 2018. This’s net activity of $22.32 million. On Friday, March 9 $518,450 worth of Abbott Laboratories (NYSE:ABT) was sold by BIRD ROGER. 905 shs valued at $53,369 were sold by Salvadori Daniel Gesua Sive on Wednesday, February 28. The insider Bracken Sharon J sold $62,056. Contreras Jaime sold $50,397 worth of Abbott Laboratories (NYSE:ABT) or 849 shs on Monday, April 23. PEDERSON MICHAEL J also sold $27,213 worth of Abbott Laboratories (NYSE:ABT) on Friday, February 16. $2.69M worth of Abbott Laboratories (NYSE:ABT) was sold by Ford Robert B.

On July, 19 Abbott Laboratories (NYSE:ABT)’s earnings release is anticipated by WallStreet, according to RTT. Analysts predict $0.71 earnings per share, which is $0.09 up or 14.52 % from 2017’s $0.62 earnings per share. This could be $1.24 billion profit for ABT assuming the current $0.71 earnings per share will become reality. After $0.59 earnings per share was announced previous quarter, analysts now see EPS growth of 20.34 % for Abbott Laboratories. Ticker’s shares touched $61.8 during the last trading session after 0.87% change.Currently Abbott Laboratories is uptrending after 41.91% change in last June 29, 2017. ABT has 1.20M shares volume. ABT outperformed the S&P 500 by 29.34%.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

A total of 15 analysts rate Abbott Laboratories (NYSE:ABT) as follows: 13 “Buy”, 2 “Hold” and 0 “Sell”. Тherefore 87% are bullish. (NYSE:ABT) has 20 ratings reports on Jun 29, 2018 according to StockzIntelligence. In Thursday, January 25 report JP Morgan maintained it with “Overweight” rating and $69 target. On Thursday, January 25 Guggenheim maintained the shares of ABT in report with “Buy” rating. On Wednesday, January 24 the stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given by RBC Capital Markets. On Wednesday, April 18 the stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Jefferies. On Wednesday, January 24 the firm earned “Buy” rating by Jefferies. On Wednesday, January 24 the company was maintained by Stifel Nicolaus. The company rating was upgraded by William Blair on Thursday, January 25. On Tuesday, January 2 the firm has “Overweight” rating given by Morgan Stanley. On Thursday, January 25 the firm has “Overweight” rating by Barclays Capital given. On Wednesday, January 24 the rating was maintained by BMO Capital Markets with “Buy”.

Abbott Laboratories manufactures and sells health care products worldwide.The firm is worth $108.35 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon.The P/E ratio is 231.46. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

More recent Abbott Laboratories (NYSE:ABT) news were announced by Streetinsider.com, Streetinsider.com and Seekingalpha.com. The first one has “Bernstein Starts Abbott Labs (ABT) at Outperform” as a title and was announced on June 28, 2018. The next is “Abbott (ABT) Says New Late-Breaking Data at ADA Underscore Significant Benefits of its FreeStyle Libre System” on June 25, 2018. And last was announced on June 27, 2018, called “Medical device makers ISRG, BSX, ABT started with bullish view at Bernstein”.

Abbott Laboratories (NYSE:ABT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: